Partner, Diagnostics
Kurma PartnersCheck size: Kurma Partners does not publish one standard check-size range across its current specialist strategies.
The official roster identifies Benjamin Belot as Partner, Diagnostics. This profile applies Kurma Partners's published strategy and does not infer undisclosed personal signing authority or a narrower individual mandate. Relevant founder fit follows the firm's thesis: Finance European healthcare innovation from company creation through growth using specialist Biofund, Diagnostics and Growth Opportunities strategies.
At firm level, Kurma Partners is aligned with finance European healthcare innovation from company creation through growth using specialist Biofund, Diagnostics and Growth Opportunities strategies. This is firm-level guidance, not an invented personal preference.
No personal pass list is public. Opportunities outside Kurma Partners's stated stages, sectors, geography or team criteria should be treated as lower fit rather than a confirmed personal rejection rule.
Lead with founder-market fit, the specific problem, differentiated product or technology, evidence of demand, market size, round stage and why the opportunity matches Kurma Partners's published focus. Address the role of Partner, Diagnostics without assuming individual check authority.
No writing has been linked yet. Kit can search for posts, interviews, and fund essays worth reading before outreach.
No podcast appearances are linked yet. Ask Kit to check for interviews that reveal how this investor thinks.
Quote coverage is incomplete. Kit can look for direct comments on markets, founders, and investment criteria.
Benjamin Belot is currently Partner, Diagnostics at Kurma Partners, as listed on the firm's official roster. Where the roster does not publish a longer biography, this profile avoids inferring prior employers, education, deals or decision authority.